Futch: HCR structures pre-approval deals in one-third and two-thirds tranches
Clark Futch · Clarke Futch – Healthcare Royalty Partners (First Meeting, EP.20) · Jun 1, 2020 · at 31:35
Clarke Futch, co-founder of Healthcare Royalty Partners, explains HCR's structuring strategy for providing commercial launch capital ahead of regulatory drug approval.
0:00 / 0:13exact quote · 13.1s
720p mp4 · rendered on demand · StarZero watermark
“So we may put a portion, maybe a third of the capital in Six months before approval, three months before approval, and then have it set up that when it's approved, the second tranche, the post-approval tranche with two-thirds of the capital goes in.”
quote is from the automated transcript, cleaned for reading: filler sounds and stutters are removed, nothing is rephrased. names can be misheard (the analysis reads context, assessments check outside sources). how →
More from Clark Futch
Futch: Orphan drugs preserve pricing power because rare disease costs are negligible to insurers
“The drugs are very expensive, but it's a very small line item on any insurance plan as opposed to cholesterol or diabetes or things that affect millions and millions of patients. So your pricing power there is better and therefore makes it more attractive and …”
Futch: Healthcare royalty diligence eliminates binary risks to focus on commercial risk
“Those three risks, the patents, manufacturing, and regulatory, are really what we view as potential binary risk. So if the product For safety reasons, gets pulled from the market because it's, have some significant side effect. That's a problem for us because …”
Futch says medical device patents can be circumvented, unlike chemical entities
“And device, typically, you can engineer around the patent, you can do it a different way. If you have a patent on the chemical entity, there's really no way to get around that.”
Futch argues dominant commercial marketing can make mediocre pharmaceutical products successful
“And you can also have a product that's maybe okay, maybe not great, maybe it's not high science, but if you have a marketing company that dominates a certain area, they can do very well with those products. We've seen that in the dermatology area, for example.”